Savara (NASDAQ:SVRA) Releases Earnings Results, Misses Estimates By $0.02 EPS

Posted by Brenda Bartman on Aug 12th, 2026

Savara (NASDAQ:SVRA – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02), FiscalAI reports.

Savara Stock Performance

Shares of NASDAQ SVRA opened at $5.57 on Wednesday. The company has a market capitalization of $1.14 billion, a P/E ratio of -9.95 and a beta of 0.29. The business’s 50-day moving average price is $5.64 and its two-hundred day moving average price is $5.49. Savara has a one year low of $2.43 and a one year high of $7.01. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47.

Hedge Funds Weigh In On Savara

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Landscape Capital Management L.L.C. bought a new stake in shares of Savara in the fourth quarter valued at about $130,000. CIBC Asset Management Inc bought a new position in Savara during the fourth quarter worth about $85,000. Jain Global LLC acquired a new stake in Savara during the third quarter valued at approximately $141,000. Brevan Howard Capital Management LP grew its stake in shares of Savara by 127.7% in the 3rd quarter. Brevan Howard Capital Management LP now owns 33,193 shares of the company’s stock valued at $118,000 after purchasing an additional 18,613 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in shares of Savara in the 3rd quarter worth approximately $90,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SVRA. Oppenheimer assumed coverage on Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 target price for the company. Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $10.14.

Read Our Latest Stock Report on Savara

Savara Company Profile

(Get Free Report)

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.